Company news

Perspective Therapeutics, Inc. news in 2026

Perspective Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

October 23, 2026

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

September 14, 2026

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

July 31, 2026

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

July 28, 2026

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

June 3, 2026

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

May 18, 2026

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

April 24, 2026

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

April 20, 2026

Perspective Therapeutics to Participate in Upcoming Investor Conferences

April 2, 2026

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

March 17, 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

March 16, 2026

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

February 17, 2026

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

February 2, 2026

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

January 9, 2026

Decks in 2026